Black Diamond Therapeutics (NASDAQ:BDTX) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Black Diamond Therapeutics (NASDAQ:BDTX) announced its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.09, Zacks reports.

Black Diamond Therapeutics Stock Performance

NASDAQ BDTX opened at $3.29 on Thursday. The stock has a market capitalization of $185.90 million, a P/E ratio of -2.47 and a beta of 2.51. Black Diamond Therapeutics has a 52 week low of $1.62 and a 52 week high of $7.66. The stock has a fifty day moving average of $4.21 and a 200-day moving average of $5.02.

Wall Street Analyst Weigh In

BDTX has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday. Piper Sandler boosted their price objective on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. Wedbush restated an “outperform” rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Finally, Raymond James began coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price target on the stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.